Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial Of AG013 For Oral Mucositis In Chemoradiation Treatment of Head and Neck Cancer; Trial Did Not Demonstrate Statistical Significance On Its Primary Endpoint
Benzinga Newsdesk